Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H25O5P |
| Molecular Weight | 364.3726 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C1=C(O)C=CC(CC2=C(C)C=C(OCP(O)(O)=O)C=C2C)=C1
InChI
InChIKey=SVXLLCKJKRYATC-UHFFFAOYSA-N
InChI=1S/C19H25O5P/c1-12(2)17-9-15(5-6-19(17)20)10-18-13(3)7-16(8-14(18)4)24-11-25(21,22)23/h5-9,12,20H,10-11H2,1-4H3,(H2,21,22,23)
| Molecular Formula | C19H25O5P |
| Molecular Weight | 364.3726 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
MB-07811 (VK-2809) is the liver-activated prodrug of a phosphonate-containing thyroid hormone receptor beta agonist MB-07344. In animal studies, it showed potent lipid and cholesterol lowering activity. Viking Therapeutics is developing MB-07811 hypercholesterolaemia and non-alcoholic fatty liver disease.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. | 2009-02 |
|
| Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs. | 2008-11-27 |
|
| Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist. | 2008-11 |
Patents
Sample Use Guides
The Phase 2 study was a randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety and tolerability of MB-07811 (VK-2809) in patients with elevated LDL-C and NAFLD. Patients were randomized to receive placebo, 5 mg VK2809 dosed daily, 10 mg VK2809 dosed every other day, or 10 mg VK2809 dosed daily for 12 weeks.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:18:05 GMT 2025
by
admin
on
Mon Mar 31 21:18:05 GMT 2025
|
| Record UNII |
R1ZW9H43ZJ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
15941848
Created by
admin on Mon Mar 31 21:18:05 GMT 2025 , Edited by admin on Mon Mar 31 21:18:05 GMT 2025
|
PRIMARY | |||
|
DTXSID10234495
Created by
admin on Mon Mar 31 21:18:05 GMT 2025 , Edited by admin on Mon Mar 31 21:18:05 GMT 2025
|
PRIMARY | |||
|
852947-39-8
Created by
admin on Mon Mar 31 21:18:05 GMT 2025 , Edited by admin on Mon Mar 31 21:18:05 GMT 2025
|
PRIMARY | |||
|
R1ZW9H43ZJ
Created by
admin on Mon Mar 31 21:18:05 GMT 2025 , Edited by admin on Mon Mar 31 21:18:05 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
